World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
71
Citations
20305
World Ranking
1824
National Ranking
779

Medicine

D-Index
74
Citations
21125
World Ranking
19379
National Ranking
9648

David W. Haas publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where David W. Haas sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 258 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

David W. Haas D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where David W. Haas sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 71 D-Index — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

David W. Haas is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily spans the field of Medicine, with a focused exploration of Infectious Diseases, Virology, Emergency Medicine, Epidemiology, and Immunology as notable subfields.

Their scholarly work concentrates strongly on HIV/AIDS-related topics, including drug development and treatment, research and interventions, and addressing health complications associated with HIV. Additionally, Haas's research includes areas such as Tuberculosis research and epidemiology, pharmacological effects and toxicity studies, and Pneumocystis jirovecii pneumonia detection and treatment.

Frequent coauthors in their publications include Richard D. Moore, Timothy R. Sterling, Keri N. Althoff, Michael A. Horberg, and Gary Maartens.

David W. Haas has contributed multiple articles to various publication venues, with some of the most frequent being:

  • Pharmacogenetics and Genomics
  • The Journal of Infectious Diseases
  • bioRxiv (Cold Spring Harbor Laboratory)
  • UNC Libraries
  • Clinical Infectious Diseases

Recent papers authored or coauthored by Haas include:

  • "A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response" (2021, Nature Genetics)
  • "HLA tapasin independence: broader peptide repertoire and HIV control" (2020, Proceedings of the National Academy of Sciences)
  • "Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV" (2024, JAMA Cardiology)
  • "Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens" (2020, Clinical Infectious Diseases)
  • "Endogenous Retroviral Envelope Syncytin Induces HIV-1 Spreading and Establishes HIV Reservoirs in Placenta" (2020, Cell Reports)

Best Publications

  • Defining the role of common variation in the genomic and biological architecture of adult human height

    Andrew R. Wood;Tonu Esko;Jian Yang;Sailaja Vedantam

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Cryptococcosis in Human Immunodeficiency Virus-Negative Patients in the Era of Effective Azole Therapy

    Peter G. Pappas;John R. Perfect;Gretchen A. Cloud;Robert A. Larsen

  • Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

    David W Haas;Heather J Ribaudo;Richard B Kim;Camlin Tierney

  • HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells.

    Kyra Oswald-Richter;Stacy M Grill;Nikki Shariat;Mindy Leelawong

  • Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

    Richard H. Haubrich;Sharon A. Riddler;A. Gregory DiRienzo;Lauren Komarow

  • Extremely low-coverage sequencing and imputation increases power for genome-wide association studies

    Bogdan Pasaniuc;Bogdan Pasaniuc;Nadin Rohland;Nadin Rohland;Paul J. McLaren;Paul J. McLaren;Kiran Garimella

  • Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial

    Jeffrey L. Lennox;Raphael J. Landovitz;Heather J. Ribaudo;Ighovwerha Ofotokun

  • Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.

    Jamison Norwood;Megan Turner;Carmen Bofill;Peter Rebeiro

  • Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

    David W. Haas;Laura M. Smeaton;Robert W. Shafer;Gregory K. Robbins

  • Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

    J Fagon;H Patrick;D W Haas;A Torres

  • The use of vancomycin and tobramycin in acrylic bone cement: biomechanical effects and elution kinetics for use in joint arthroplasty.

    John Klekamp;John M. Dawson;David W. Haas;David DeBoer

  • CD1d-restricted Human Natural Killer T Cells Are Highly Susceptible to Human Immunodeficiency Virus 1 Infection

    Alison Motsinger;David W. Haas;Aleksandar K. Stanic;Luc Van Kaer

  • Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study

    Heather J. Ribaudo;David W. Haas;Camlin Tierney;Richard B. Kim

  • Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)

    Stephen J Gange;Mari M Kitahata;Michael S Saag;David R Bangsberg

  • The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.

    Mustafa A Noor;Rex A Parker;Edward O'Mara;Dennis M Grasela

  • Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing

    Unknown

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

    Roseann S. Gammal;Michael H. Court;Cyrine E. Haidar;Otito Frances Iwuchukwu

  • Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease

    J. W. Baddley;J. R. Perfect;R. A. Oster;R. A. Larsen

  • Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment.

    David W. Haas;Mark P. McAndrew

  • HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins

    Zabrina L. Brumme;Zabrina L. Brumme;Mina John;Jonathan M. Carlson;Chanson J. Brumme

  • Treatment of Gram-positive Nosocomial Pneumonia Prospective Randomized Comparison of Quinupristin/Dalfopristin versus Vancomycin

    J. Y. Fagon;H. Patrick;D. W. Haas;A. Torres

Frequent Co-Authors

Marylyn D. Ritchie
Marylyn D. Ritchie University of Pennsylvania
Jacques Fellay
Jacques Fellay École Polytechnique Fédérale de Lausanne
Bruce D. Walker
Bruce D. Walker Harvard University
Edward P. Acosta
Edward P. Acosta University of Alabama at Birmingham
Steven G. Deeks
Steven G. Deeks University of California, San Francisco
Roy M. Gulick
Roy M. Gulick Cornell University
Timothy R. Sterling
Timothy R. Sterling Vanderbilt University Medical Center
David B. Clifford
David B. Clifford Washington University in St. Louis
Eric S. Daar
Eric S. Daar Lundquist Institute
Paul I. W. de Bakker
Paul I. W. de Bakker Vertex Pharmaceuticals (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to a variety of allied health and science careers. For professionals interested in blending healthcare with technology and data management, exploring cahiim accredited health information management programs online can provide essential skills for managing patient data and health records.

Those looking for quicker credentialing options might consider earning an accredited fast medical billing and coding certificate online. This path is ideal for entering the healthcare administration field swiftly while building expertise in medical coding and billing processes.

For graduates focused on clinical or research roles, various online medical programs offer flexible routes to advance their medical knowledge without pausing their careers. These programs range from physician assistant studies to specialized medical certifications.

Public health is another vital career avenue connected to microbiology. Prospective students can explore accredited online mph programs easy to get into that prepare professionals to tackle community health challenges and epidemiology, complementing a microbiology background.

Best Scientists Citing David W. Haas

Trending Scientists

Recently Published Articles